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Abstract
Canarypox viruses (CNPV) carrying the coding sequence of VP2 protein from infectious bursal dis-
ease virus (IBDV) were obtained. These viruses were able to express VP2 protein in vitro and to in-
duce IBDV-neutralizing antibodies when inoculated in specific pathogen-free chickens demonstrat-
ing that CNPV platform is usefulness to develop immunogens for chickens.
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Canarypox virus (CNPV), a member of the avipo-
xvirus genus, has been successfully evaluated as recombi-
nant expression vectors for vaccines development. In this
sense, the CNPV platform has been used to give rise protec-
tive immune response against various pathogens in differ-
ent mammalian species (reviewed in Poulet et al., 2007;
Brun et al., 2008). Moreover, some of them have reached
the market as licensed products commercialized by Merial
(a Sanofi Pasteur Company).
Based on the fact that no reports have been published
using this viral vector to prevent diseases in chickens, we
decided to obtain and evaluate recombinant CNPV as im-
munogen for that species selecting VP2 protein from infec-
tious bursal disease virus (IBDV) as a model antigen. IBDV
is the etiologic agent of infectious bursal disease (IBD), a
highly contagious and severe disease that causes significant
economic losses in the poultry industry worldwide. IBDV
replicates primarily in B lymphocyte precursors developing
within the bursa of Fabricious (Müller et al., 2003). De-
pending on the virulence of IBDV strain and the age of the
infected chickens, IBD is manifested in two ways. In some
cases occur with clinical symptoms and may cause up to
20% or more mortality in chickens 3 weeks of age and
older. Otherwise, and more important, is evidenced by a se-
vere, prolonged immunosuppression of chickens infected
at an early age (Eterradossi and Saif, 2008). The VP2 ma-
ture protein (of 441 residues) is the only structural
component of the IBDV icosahedral capsid, and thus re-
sponsible to the interaction with host cell receptors. VP2
constitutes the major host-protective antigen as it contains
conformation-dependent epitopes responsible for eliciting
neutralizing antibodies (Müller et al., 2003).
In this work, we obtained recombinant canarypox vi-
ruses that express IBDV VP2 protein and showed their
immunogenicity when inoculated in specific pathogen-free
(SPF) chickens.
The first step was the construction of the transference
vector (named TV-CN048-VP2) carrying foreign genes
flanked by viral regions (position 57,247, inside CNPV046,
to 59,528, inside CNPV048, (Tulman et al., 2004)) which
serve as points of recombination with CNPV genome. The
selected gene was the coding sequence for VP2 mature pro-
tein from the Argentinean IBDV isolate LD-847-04, sero-
type I (vp2 gene, NCBI accession No. JF965438). This
nucleotide sequence was obtained as described before
(Zanetti et al., 2012a) and subcloned into TV-CN048-GUS
plasmid which was previously designed and built in our
laboratory (Zanetti et al., 2012b). The final construction
was the transference vector (8,452 bp, Figure 1A), which
carried vp2 gene downstream of the poxviral synthetic
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early/late promoter (pE/L) and the expression cassette for
the GUS enzyme (uid A gene under regulation of vaccinia
virus H6 gene promoter), both flanked by CNPV genomic
sequences.
The vp2 gene identity was confirmed by DNA se-
quencing using an ABI PRISM 3130 genetic analyzer (Ap-
plied Biosystem, Japan). Then, the final plasmid TV-
CN048-VP2 was transfected, by LipofectinTM (Invitrogen,
Carlsbad, CA, USA), into SPF primary chicken embryo
fibroblasts (CEFs) previously infected with CNPV (Abba-
tista95 vaccine strain provided by LaDiPreVet laboratory,
La Plata, Argentina). Recombinant viral clones forming
GUS positive plaques were visualized with X-Gluc (5-bro-
mo-4-chloro-3-indolyl--D-glucuronic acid, Inalco, Italy)
overlay. After five rounds of purification, 100% of blue
plaques were visualized and CN048-VP2 viruses were am-
plified and molecularly characterized. Firstly, total DNA
extracted from infected CEFs was analysed by Southern
Blot (Ferrer et al., 2011). The purity of recombinant viruses
(absence of wild type genome) and the insertion of the VP2
expression cassette were confirmed by hybridization with
32P-labelled CNPV048 probe (genomic positions 58,948 to
59,528) or vp2 gene probe, respectively (Figure 1B). There-
after, the expression of VP2 protein from recombinant vi-
ruses was evaluated by Indirect Immunofluorescence (IIF)
and Western blot (WB) assays in DF1 (ATCC, CRL-
12203) infected cells as previously described (Zanetti et al.,
2012a). The expression of VP2 protein (green fluores-
cence) was clearly observed in the cytoplasm of CN048-
VP2 infected cells but no fluorescence was evidenced in
CNPV-infected cells (Figure 1 C). Besides, a band of ap-
proximately 37 kDa was only detected by WB in DF1 cells
infected with the recombinant CN048-VP2 (Figure 1D).
Taken together, these results demonstrated the capability of
232 Zanetti et al.
Figure 1 - Molecular characterization of CN048-VP2 recombinant virus. (A) Scheme of the transference vector TV-CN048-VP2. L: 600 bp fragment
started in position 59,528. R: 1,700 bp fragment until position 57,247 encompassing the final region of CNPV048 gene, the complete CNPV047 gene and
the initial region of CNPV046 gene. (B) Autorradiographies of Southern blot analysis using a 600 bp fragment of CNPV048 gene (positions 58,927 to
59,528) or vp2 gene as 32P-labelled probes. (C) Indirect immunofluorescence assay in DF1 cells infected with CN048-VP2 or non-recombinant CNPV vi-
ruses; white bars represents 25 m. (D) Western blot assay: protein extracts were resolved in 12% SDS-PAGE and VP2 protein (indicated by an arrow)
was detected using a rabbit polyclonal serum against IBDV-VP2 protein. Apparent molecular masses are indicated in kDa. WT: non-recombinant CNPV
virus, R: recombinant CN048-VP2 virus. (E) Multiple-step growth curve of CNPV and CN048-VP2 in CEFs. The PFU/mL at each point is the mean of
two independent experiments; errors bars represent standard deviations.
CN048-VP2 virus to in vitro express the IBDV VP2 protein
with the predicted molecular weight for the mature protein.
Thereafter, replication ability of recombinant and parental
CNPVs was assessed by performing a multiple-step growth
curve. Briefly, CEFs were infected at 0.01 plaque-forming
units (PFU)/cell with CNPV or CN048-VP2 viruses.
Supernatant and cells were collected together at different
hours post infection (0, 5, 16, 24, 48 and 72 h) and fro-
zen/thawed three times before tittering by duplicate in
CEFs. The viral titer (PFU/mL) was calculated as the aver-
age value of the viral titers obtained in two independent ex-
periments. Recombinant and wt CNPVs had the same
growth curves indicating that the insertion of foreign se-
quences interrupting CNPV048 gene did not modify the vi-
ral replication capability in CEFs (Figure 1E). Then, the ge-
netic stability of the recombinant viruses was evaluated by
ten consecutive multiple-step growth passages on CEFs.
After the 10th passage recombinant viruses produced 100%
of blue plaques and the expression of VP2 protein was con-
firmed by WB (data not shown).
Then, the immunogenicity of CN048-VP2 was evalu-
ated in SPF White Leghorn chickens randomly separated in
four groups of five birds each. The chickens (11-days-old)
were intramuscularly (i.m.) immunized with CNPV or
CN048-VP2 (5.5 x 105 PFU/bird) or orally vaccinated with
D78 live vaccine (2.7 x 103 PFU/bird) or PBS (50 L). All
birds were boosted at 32 and 53 days-old with the same
inocula. At different times (11, 32, 53 and 74 days old)
blood samples were collected from the wing vein to evalu-
ate the induced specific humoral response. The experiment
was performed in the animal facilities at the Biotechnology
Institute (INTA) in compliance with guidelines of Institu-
tional Committee for the Use and Care of Experimentation
Animals (CICUAE-INTA) that approved the protocol
18/2012 based on both National Institute of Health Guide
for the care and use of laboratory animal and Directive
2010/63/EU of the European Parliament on the protection
of animals used for scientific purposes. Sera from the same
experimental group were pooled and analyzed by an in vi-
tro IBDV neutralization test as described before (Jackwood
et al., 1982; Zanetti et al., 2012a). As expected, neither the
sera obtained from 11 days old birds (pre-immune status)
nor the samples collected from CNPV or PBS groups
showed IBDV-specific antibodies. However, IBDV neu-
tralizing antibodies were detected in sera from chickens
vaccinated with CN048-VP2 or D78. Besides, the sero-
neutralizing titer increased after each CN048-VP2 immnu-
nization indicating that the anti-vector immunity did not
affect the efficacy of the booster vaccinations. The IBDV-
D78 live vaccine induced higher level of neutralizing anti-
bodies than the recombinant virus (Table 1).
At present, in the poultry industry, IBD is controlled
by immunization with attenuated live or inactivated IBDV
vaccines. However, these vaccines have several disadvan-
tages. The inactivated vaccines are expensive and must be
administered to birds previously immunizated with live
vaccines (Müller et al., 2003). Attenuated IBDV vaccines
have to be applied once the IBDV maternal antibodies have
decreased and could cause moderate bursal atrophy and/or
immunosuppresion. This fact allowed both the infection
with other pathogens and poor immune response to other
vaccines. More recently, the use of an immune complex
vaccine (containing a live IBDV strain and an anti-IBDV
hyperimmune serum, [Müller et al., 2003]) or a turkey
herpesvirus-based vector vaccine (recombinant HVT ex-
pressing IBDV-VP2 protein, [Poulet et al., 2007]) has been
implemented to the control of IBD in commercial poultry
populations. Although these vaccines are effective in the
presence of maternal antibodies inducing lifelong immu-
nity, they have the major disadvantage of their high cost
due to the addition of anti-serum (immune complex) or to
the requirements of a cold chain to maintain the viability of
HVT vector. In contrast, the high physical stability of
CNPV-based viral vector allows the formulation of either
freeze-dried or liquid vaccines with shelf-lives up to 2 years
at room temperture (Poulet et al., 2007).
In this report, we demonstrated that CN048-VP2 vi-
ruses were capable to elicit an IBDV specific humoral re-
sponse with the presence of neutralizing antibodies in the
vaccinated chickens. Due to neutralizing epitopes located
on VP2 are discontinuous, it could be assumed that the VP2
protein expressed from CN048-VP2 had a correct
conformational structure. In addition to that, we demon-
strated that anti-canarypox vector immune response would
not interfere with the following immunizations since the
values of IBDV-seroneutralizing titers increased after each
booster. This result agreed with observations of Poulet et
al. (2007) who described that canarypox viral vectors are
chosen for vaccination programs that require several boost-
ers to achieve protective immunity. The immunization of
chickens with CN048-VP2 viral vector elicited lower neu-
tralizing antibody titers than replicative D78 live vaccine,
but the poxvirus vector could also be inducing a cellular im-
mune response contributing to protection against IBDV in-
fections (Müller et al., 2003). For that reason, further
experiments have to be performed to evaluate both protec-
tion and cellular immune response induced by CN048-VP2
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Table 1 - IBDV-neutralizing titers in the sera of vaccinated birds
Age (days)
32 53 74
CN048-VP2 16 32 512
IBDV-D78 512 1024 1024
Seroneutralizing titers are expressed as the reciprocal of the last serum di-
lution that completely neutralized 100 TCID50 (50% tissue culture infec-
tive doses) units of IBDV strain LZD. CN048-VP2: recombinant CNPV
virus expressing IBDV VP2 mature protein, IBDV-D78: live commercial
IBDV vaccine (strain D78). IBDV-specific antibodies were negative both
in the sera from 11 days old chicks (pre-immune) as in the samples col-
lected from CNPV or PBS immunized birds.
vaccination of chickens (with and without IBDV maternal
antibodies). Besides, other routes of administration of
CN048-VP2 consistent with the use in poultry industry
such as subcutaneous immunization or wing-web scari-
fication will be evaluated. Finally, a recombinant CNPV
co-expressing cytokines with VP2 protein will be obtained
with the aim to improve the specific immune response in
chickens.
In conclusion, we demonstrated that recombinant
canarypox viruses could be effective for developing novel
vaccines against poultry diseases. To our knowledge this is
the first report of immunization of chickens with canarypox
virus-based vector.
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